Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Prestwick3_000039

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Prestwick3_000039

    ACTIVE PHARMA INGREDIENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 719Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zydus Pharm’s Generic Diflunisal Receives Approval In US
    Zydus Pharm’s Generic Diflunisal Receives Approval In US

    20 Jun 2017

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203547

    FDA
    20 Jun 2017
    Share Share
    IDT Australia release on FDA nod for 23 generics begs the question: Where's the beef?
    IDT Australia release on FDA nod for 23 generics begs the question: Where's the beef?

    14 Apr 2015

    // EJ Lane FIERCE PHARMA ASIA

    http://www.fiercepharmaasia.com/story/idt-australia-release-fda-nod-23-generics-begs-question-wheres-beef/2015-04-14

    EJ Lane FIERCE PHARMA ASIA
    14 Apr 2015
    Share Share
    FDA’s Anti-Franchising Policy: What Is It and Where Did It Come From?
    FDA’s Anti-Franchising Policy: What Is It and Where Did It Come From?

    04 Mar 2015

    // Kurt R. Karst FDA LAW BLOG

    http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/03/fdas-anti-franchising-policy-what-is-it-and-where-did-it-come-from.html

    Kurt R. Karst FDA LAW BLOG
    04 Mar 2015
    Share Share